Mitsubishi Electric Achieves World’s First Mechanism for Elucidating Ozone Oxidation Enhanced with Negative Ions




Mitsubishi Electric Achieves World’s First Mechanism for Elucidating Ozone Oxidation Enhanced with Negative Ions

Reduces surface-bound viruses, bacteria and odors for safe, secure, and comfortable indoor environment

TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that in collaboration with Professor Toshiaki Kamachi and colleagues from the School of Life Science and Technology at Institute of Science Tokyo (Science Tokyo) they have achieved the world’s first mechanism for elucidating the combined use of negative ions to enhance the oxidative action of ozone. In their joint study, they discovered that dissolving negative ions in the moisture surrounding viruses and other microorganisms lowers the pH due to nitrate-containing components derived from the negative ions, which in turn enhances the oxidative action of ozone in the moisture, enabling a strong reduction of viruses and bacteria even at low ozone concentrations. Mitsubishi Electric confirmed the reduction of bacteria and odors in low ozone concentrations of 50 parts per billion (ppb) in addition to specific viruses reported previously.

Buildings are becoming more airtight and better insulated, raising concerns about inadequate indoor ventilation and unhygienic conditions. Ozone’s oxidative action has traditionally been used to maintain indoor hygiene, but ozone alone has faced challenges in terms of the durability and stability of its sanitizing effects. It is also known that ozone’s reduction of viruses and bacteria increases when used with negative ions and varies with pH. However, the specific chemical species of the negative ions and their pH-controlling effects had not been clarified.

For the full text, please visit: www.MitsubishiElectric.com/news/

Contacts

Customer Inquiries
Advanced Technology R&D Center

Mitsubishi Electric Corporation

Fax: +81-6-6497-7285

www.MitsubishiElectric.com/ssl/contact/company/rd/form.html
www.MitsubishiElectric.com/en/about/rd/

Media Inquiries
Takeyoshi Komatsu

Public Relations Division

Mitsubishi Electric Corporation

Tel: +81-3-3218-2332

prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/en/pr/

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors




Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET

BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.

Webcast, Presentation Slides and Conference Call Information

Immunome will host a webcast and conference call on Monday, December 15, 2025, at 8:30 a.m. ET / 5:30 a.m. PT to discuss the Phase 3 RINGSIDE trial topline results. A live webcast, which will include presentation slides, can be accessed using this link or by visiting the Events and Presentations section of the Immunome website at https://investors.immunome.com/events. The conference call can be accessed by clicking on the call link and completing the online registration form, which will enable the selection of a dial-in number or callback from the system. A live question-and-answer session will follow the prepared remarks. Participants wishing to ask a question must do so via the conference call; the webcast will be listen-only. After the live webcast, the event will remain archived on the Immunome website for 90 days. 

About Immunome, Inc.

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.

Contacts

Investor Contact:

Max Rosett

Chief Financial Officer, Immunome

investors@immunome.com

Media Contact:
Nicole Foderaro

Real Chemistry

media@immunome.com

GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among Others – ResearchAndMarkets.com




GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “GMP Cytokine Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global GMP cytokine market is expected to grow with a CAGR of 8.4% from 2025 to 2031. The major drivers for this market are the increasing demand for immunotherapies, the rising adoption of personalized medicine, and the growing focus on cancer research. The future of the market looks promising with opportunities in the cell/gene therapy and tissue-engineered product markets.

• Within the type category, interleukin is expected to witness the highest growth over the forecast period.
• Within the application category, cell/gene therapy is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the GMP Cytokine Market

The GMP cytokine market is evolving as advanced therapeutics expand, focusing on personalized medications and innovative manufacturing techniques. Key trends include the move towards personalized medicine, bioprocess optimization, growth of contract manufacturing services, better delivery technologies, and the adoption of advanced analytics and AI. These trends are transforming the market into a technologically advanced sector prioritizing precision and efficiency.

Recent Developments in the GMP Cytokine Market

Recent developments include the shift to animal-free expression systems to enhance safety, expansion of commercial-scale production, regulatory harmonization, and strategic alliances. These factors increase reliability, safety, and accessibility while fostering efficient global collaboration in the GMP cytokine market.

Strategic Growth Opportunities in the GMP Cytokine Market

The market is poised for strategic growth within cell and gene therapy, cancer immunotherapy, regenerative medicine, vaccine development, and biosimilars. These opportunities leverage the unique benefits of GMP cytokines, emphasizing innovation and specialization in therapeutic applications.

GMP Cytokine Market Drivers and Challenges

Growth is driven by rising chronic diseases, expanding cell and gene therapy markets, technological advances, supportive regulatory environments, and increased R&D investments. Challenges include high manufacturing costs, stringent regulatory compliance, and supply chain risks. Navigating these factors will shape a dynamic and innovative market landscape.

Country-Wise Outlook for the GMP Cytokine Market

Countries are advancing in GMP cytokine production tailored to their economic and regulatory contexts. The US leads with robust R&D and regulatory support. China’s emphasis on local manufacturing boosts accessibility. Germany focuses on high-quality production and regulation. India and Japan invest in local R&D, aiding market growth through cost-efficiency and strategic focuses respectively.

Key Topics Covered

1. Executive Summary

2. Market Overview

2.1 Background and Classifications

2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Global GMP Cytokine Market Trends and Forecast

3.2 Industry Drivers and Challenges

3.3 PESTLE Analysis

3.4 Patent Analysis

3.5 Regulatory Environment

4. Global GMP Cytokine Market by Type

4.1 Overview

4.2 Attractiveness Analysis by Type

4.3 TNF: Trends and Forecast (2019-2031)

4.4 Interleukin: Trends and Forecast (2019-2031)

4.5 Growth Factor: Trends and Forecast (2019-2031)

4.6 Others: Trends and Forecast (2019-2031)

5. Global GMP Cytokine Market by Application

5.1 Overview

5.2 Attractiveness Analysis by Application

5.3 Cell/Gene Therapy: Trends and Forecast (2019-2031)

5.4 Tissue-Engineered Products: Trends and Forecast (2019-2031)

5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview

6.2 Global GMP Cytokine Market by Region

7. North American GMP Cytokine Market

8. European GMP Cytokine Market

9. APAC GMP Cytokine Market

10. RoW GMP Cytokine Market

11. Competitor Analysis

11.1 Product Portfolio Analysis

11.2 Operational Integration

11.3 Porter’s Five Forces Analysis

11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis

12.2 Growth Opportunity Analysis

12.2.1 Growth Opportunities by Type

12.2.2 Growth Opportunities by Application

12.3 Emerging Trends in the Global GMP Cytokine Market

12.4 Strategic Analysis

12.4.1 New Product Development

12.4.2 Certification and Licensing

12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis

13.2 Bio-Techne

13.3 PeproTech

13.4 CellGenix

13.5 Miltenyi Biotec

13.6 Cytiva

13.7 Lonza

13.8 ReproCELL

13.9 Sino Biological

13.10 Akron Biotech

13.11 Creative Bioarray

For more information about this report visit https://www.researchandmarkets.com/r/42l1pl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications – ResearchAndMarkets.com




Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peptide Cancer Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global peptide cancer vaccine market is expected to grow with a CAGR of 19.8% from 2025 to 2031. The major drivers for this market are the increasing demand for targeted cancer therapies, the rising government funding for cancer research, and the growing focus on personalized cancer treatments.

The future of the global peptide cancer vaccine market looks promising with opportunities in the breast cancer, lung cancer, melanoma, and prostate cancer markets.

Key Highlights by Segment

• Within the type category, galinpepimut-S is expected to witness the highest growth over the forecast period.
• Within the application category, breast cancer is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Peptide Cancer Vaccine Market

The peptide cancer vaccine market is transforming with trends aimed at overcoming past limitations and enhancing personalized medicine. Key trends include developing personalized neoantigen vaccines, utilizing combination therapies with checkpoint inhibitors, and advancing adjuvant and delivery systems. The integration of AI and big data is streamlining the identification of effective peptide candidates, accelerating R&D processes, and improving patient outcomes.

Recent Developments in the Peptide Cancer Vaccine Market

Recent developments in the peptide cancer vaccine market include late-stage clinical trials of personalized vaccines, strategic partnerships between major pharmaceutical and biotech companies, and the introduction of advanced adjuvant technologies. The market is witnessing increased FDA approvals and the expansion of target indications to encompass a broader range of cancers. These advancements foster a professional and technology-driven industry ecosystem.

Strategic Growth Opportunities in the Peptide Cancer Vaccine Market

Significant strategic growth opportunities are emerging in personalized medicine, combination therapies, and the development of adjuvant and delivery partnerships. The growing focus on early-stage clinical trials and emerging economies presents more growth avenues. Companies are encouraged to diversify and specialize in unique applications to cater to various patient demographics and healthcare providers.

Peptide Cancer Vaccine Market Drivers and Challenges

The market is driven by factors such as rising cancer incidence, advancements in genomic sequencing, and a favorable regulatory environment. Increased investments in immuno-oncology also bolster growth. However, challenges like low immunogenicity, high development costs, and tumor-induced immunosuppression pose significant obstacles. Addressing these challenges is crucial for maintaining a competitive edge.

Country-Wise Outlook for the Peptide Cancer Vaccine Market

• United States: Leads with R&D investments in personalized vaccines and combination therapies.
• China: Expands rapidly with government support and growing public-private partnerships.
• Germany: Focuses on innovative vaccine formulations and universal approaches.
• India: Sees growth through affordable and accessible treatments.
• Japan: Invests in AI and data-driven developments with a focus on safety and efficacy.

Key Topics Covered

1. Executive Summary

2. Market Overview

2.1 Background and Classifications

2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Global Peptide Cancer Vaccine Market Trends and Forecast

3.2 Industry Drivers and Challenges

3.3 PESTLE Analysis

3.4 Patent Analysis

3.5 Regulatory Environment

4. Global Peptide Cancer Vaccine Market by Type

4.1 Overview

4.2 Attractiveness Analysis by Type

4.3 ITK-1: Trends and Forecast (2019-2031)

4.4 GRN-1201: Trends and Forecast (2019-2031)

4.5 TPIV200: Trends and Forecast (2019-2031)

4.6 TPIV110: Trends and Forecast (2019-2031)

4.7 UV1: Trends and Forecast (2019-2031)

4.8 Galinpepimut-S: Trends and Forecast (2019-2031)

4.9 TARP 27-35: Trends and Forecast (2019-2031)

4.10 HER-Vaxx: Trends and Forecast (2019-2031)

4.11 Others: Trends and Forecast (2019-2031)

5. Global Peptide Cancer Vaccine Market by Application

5.1 Overview

5.2 Attractiveness Analysis by Application

5.3 Breast Cancer: Trends and Forecast (2019-2031)

5.4 Lung Cancer: Trends and Forecast (2019-2031)

5.5 Melanoma: Trends and Forecast (2019-2031)

5.6 Prostate Cancer: Trends and Forecast (2019-2031)

5.7 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview

6.2 Global Peptide Cancer Vaccine Market by Region

7. North American Peptide Cancer Vaccine Market

8. European Peptide Cancer Vaccine Market

9. APAC Peptide Cancer Vaccine Market

10. RoW Peptide Cancer Vaccine Market

11. Competitor Analysis

11.1 Product Portfolio Analysis

11.2 Operational Integration

11.3 Porter’s Five Forces Analysis

11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis

12.2 Growth Opportunity Analysis

12.2.1 Growth Opportunities by Type

12.2.2 Growth Opportunities by Application

12.3 Emerging Trends in the Global Peptide Cancer Vaccine Market

12.4 Strategic Analysis

12.4.1 New Product Development

12.4.2 Certification and Licensing

12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis

13.2 Boston Biomedical

13.3 Ultimovacs

13.4 BrightPath Biotherapeutics

13.5 TapImmune

13.6 Immatics

13.7 Sellas

13.8 Imugene

13.9 VAXON Biotech

13.10 Generex Biotechnology

13.11 ISA Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/5nxfls

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Anova Launches Free AI-enabled Clinical Trial Patient Matching Solution as Part of a Global Just-in-time Research Network




Anova Launches Free AI-enabled Clinical Trial Patient Matching Solution as Part of a Global Just-in-time Research Network

• Anova launches a free AI-enabled patient matching solution that uses proprietary algorithms to connect patients to 200,000+ open clinical trials with high-confidence eligibility matching
• The AnovaOS^® platform speeds trial enrollment by automating screening, integrating into existing study coordination workflows, and enabling participation in a global just-in-time research network
• By removing cost barriers, Anova expands access to advanced research technology, strengthens collaboration across 60,000+ research sites and 15,000+ sponsors, and helps bring promising new therapies to patients faster

LONDON & CHICAGO–(BUSINESS WIRE)–#AI–Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, has today announced the launch of its new AI-enabled patient matching solution as part of a global just-in-time research network and clinical trial infrastructure. The solution matches patients to open and accruing clinical trials and promising investigational products for compassionate use. The platform, available at no cost to participating research sites, accelerates trial enrollment by using AI and proprietary algorithms to identify patients who meet eligibility criteria with a high degree of certainty – matching demographic, molecular, and clinical history data to structured elgibility criteria from across 200,000+ open and accruing clinical trials.

Clinical trial enrollment remains one of the greatest challenges in drug development, with nearly 80% of studies experiencing delays due to recruitment difficulties. This new offering helps to address that barrier by providing research teams with an easy-to-use solution that integrates seamlessly into existing clinical workflows, streamlining the process of screening patients for trials.

The AnovaOS^® SaaS solution streamlines access for those involved in research, accelerates throughput of new therapies, and provides a framework for collaboration, quality evidence generation and scientific insight. The platform enables clinical trial sponsors to connect with over 60,000 research-ready clinical research sites globally. Sites are increasingly using the platform to identify clinical trial opportunities for their patients and practices.

Key features of the patient matching solution include:

• Automated eligibility screening against trial protocols.
• Secure, privacy-protected data handling to ensure patient confidentiality.
• Real-time updates on available trials and criteria changes.
• Scalable access for sites ranging from large academic centers to community practices.

“By making this solution free to access, we are empowering research sites of all sizes to connect the right patients with the right studies when treatment decisions are being made,” said Christopher Beardmore, CEO and Co-founder of Anova. “The only way to present clinical trial options to patients is when the decision to select the next line of therapy is being made. That cannot be done when study teams rely on medical record review, pathology results and potential patient lists. Patients are lost to study (and lose access to promising new treatments) when that approach is used. The AnovaOS solution not only provides a study matching capability, but supports a global just-in-time network to enable access to any investigational product just-in-time, either through a clinical trial or compassionate use.”

By removing cost barriers, Anova aims to broaden access to cutting-edge technology for clinical sites, foster more inclusive participation in research, help sponsors and investigators reach enrollment goals and bring promising new treatments more quickly to patients in need.

To find out more, contact info.us@anovaevidence.com.

About Anova

Anova Enterprises, Inc. (Anova) is a technology-enabled concierge research organization committed to accelerating clinical development for start-up biopharmaceutical companies utilizing the company’s proprietary technology platform (AnovaOS^®). For more information, please visit www.anovaevidence.com.

Chris Beardmore, Co-Founder and CEO

chris@anovaevidence.com

Martin Walsh, Co-Founder and President

Anova Enterprises, Inc.

martin@anovaevidence.com

www.anovaevidence.com
Twitter feed at @anovaevidence

Follow Anova at www.linkedin.com/company/anovaevidence

Contacts

Anova Enterprises, Inc.
Woodfield Preserve, 10 N. Martingale Road, Suite 560

Schaumburg, IL 60173

(224) 218-2408

info.us@anovaevidence.com

Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031 – APAC Leads Industry Growth as Demand for Pain Management Soars – ResearchAndMarkets.com




Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031 – APAC Leads Industry Growth as Demand for Pain Management Soars – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global diabetic neuropathy market is expected to grow with a CAGR of 5% from 2025 to 2031. The major drivers for this market are the increasing prevalence of diabetes worldwide, the rising awareness about neuropathic disorders, and the growing demand for effective pain management. The future of the global diabetic neuropathy market looks promising with opportunities in the online pharmacy, hospital pharmacy, and retail pharmacy markets.

Key Highlights by Segment

• Within the type category, subcutaneous is expected to witness the highest growth over the forecast period.
• Within the application category, online pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Diabetic Neuropathy Market

The diabetic neuropathy market is undergoing significant changes due to advancements in understanding nerve damage, improved treatment methodologies, and technological integration. Focus has shifted towards disease modification, with emerging interest in non-pharmacological treatments and personalized medicine. Emphasis on early diagnosis using novel biomarkers is also increasing, while digital health tools are gaining traction for better patient management.

Recent Developments in the Diabetic Neuropathy Market

Recent developments in the market include advances in gene therapy and medical devices, such as the FDA-approved spinal cord stimulation systems. There is a rise in novel drug candidates targeting various pathways for nerve damage and a push towards better diagnostic tools. Focus has also increased on managing autonomic neuropathy, highlighting improvements in diagnosis and treatment strategies.

Strategic Growth Opportunities in the Diabetic Neuropathy Market

Significant growth opportunities exist in pain management solutions, disease-modifying therapies, and diabetic foot ulcer prevention. The increasing prevalence of autonomic neuropathy presents opportunities for targeted diagnostics and treatments. Development of early diagnostic tools and screening programs is another area for potential growth, allowing for timely interventions and better patient outcomes.

Diabetic Neuropathy Market Drivers and Challenges

The factors responsible for driving the diabetic neuropathy market include:

• Rising Global Prevalence of Diabetes: The increasing diabetic population necessitates more treatments for neuropathy.
• Increasing Awareness and Diagnosis Rates: Improved awareness and diagnostics fuel treatment demand.
• Aging Population: Older adults are more susceptible to diabetes complications, expanding the patient base.
• Advances in Research and Development: Innovations in R&D provide more effective treatments.
• Unmet Medical Need for Disease-Modifying Therapies: Demand for therapies that address nerve damage prompts innovation.

Challenges in the diabetic neuropathy market include:

• Lack of Definitive Cure: Current therapies focus on symptom management, not cures.
• Late Diagnosis and Disease Progression: Delays in diagnosis hamper treatment effectiveness.
• High Cost of Novel Therapies: The expense of new therapies can limit access and adoption.

Country-Wise Outlook for the Diabetic Neuropathy Market

The market is progressing with innovative therapies, including gene therapies in the U.S. and neurostimulation devices in Japan. In China and India, the focus is shifting towards local R&D and improved healthcare infrastructures to handle DPN effectively. Germany emphasizes combining medicinal and non-medicinal treatments, reflecting a comprehensive approach to manage complications.

Key Topics Covered

1. Executive Summary

2. Market Overview

2.1 Background and Classifications

2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Global Diabetic Neuropathy Market Trends and Forecast

3.2 Industry Drivers and Challenges

3.3 PESTLE Analysis

3.4 Patent Analysis

3.5 Regulatory Environment

4. Global Diabetic Neuropathy Market by Type

4.1 Overview

4.2 Attractiveness Analysis by Type

4.3 Oral: Trends and Forecast (2019-2031)

4.4 Subcutaneous: Trends and Forecast (2019-2031)

4.5 Intravenous: Trends and Forecast (2019-2031)

5. Global Diabetic Neuropathy Market by Application

5.1 Overview

5.2 Attractiveness Analysis by Application

5.3 Online Pharmacies: Trends and Forecast (2019-2031)

5.4 Hospital Pharmacies: Trends and Forecast (2019-2031)

5.5 Retail Pharmacies: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview

6.2 Global Diabetic Neuropathy Market by Region

7. North American Diabetic Neuropathy Market

8. European Diabetic Neuropathy Market

9. APAC Diabetic Neuropathy Market

10. RoW Diabetic Neuropathy Market

11. Competitor Analysis

11.1 Product Portfolio Analysis

11.2 Operational Integration

11.3 Porter’s Five Forces Analysis

11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis

12.2 Growth Opportunity Analysis

12.2.1 Growth Opportunities by Type

12.2.2 Growth Opportunities by Application

12.3 Emerging Trends in the Global Diabetic Neuropathy Market

12.4 Strategic Analysis

12.4.1 New Product Development

12.4.2 Certification and Licensing

12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis

13.2 Pfizer

13.3 Janssen Pharmaceuticals

13.4 Eli Lilly and Company

13.5 ACTAVIS

13.6 Cephalon

13.7 MEDA Pharma

13.8 GlaxoSmithKline

13.9 NeuroMetrix

13.10 Johnson & Johnson Services

13.11 Novartis

For more information about this report visit https://www.researchandmarkets.com/r/ibhms4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Pfizer Declares First-Quarter 2026 Dividend




Pfizer Declares First-Quarter 2026 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Category: Financial

Contacts

Media Contact: PfizerMediaRelations@Pfizer.com

Investor Contact: IR@Pfizer.com

Red Seaweed Extract Global Market Size, Trends and Competition Analysis 2025-2031 Featuring DuPont, Cargill, Shemberg, Qingdao Nanshan Seaweed, Gelymar and More – ResearchAndMarkets.com




Red Seaweed Extract Global Market Size, Trends and Competition Analysis 2025-2031 Featuring DuPont, Cargill, Shemberg, Qingdao Nanshan Seaweed, Gelymar and More – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Red Seaweed Extract Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global red seaweed extract market is expected to grow with a CAGR of 6.6% from 2025 to 2031. The major drivers for this market are the increasing demand for natural plant-based food ingredients, the rising consumer awareness of health & wellness, and the growing use in pharmaceuticals cosmetics & agriculture.

The future of the global red seaweed extract market looks promising with opportunities in the food & beverage, paint, cosmetic, animal feed additive, pharmaceutical, and industrial application markets.

Key Highlights by Segment

• Within the type category, powder is expected to witness the highest growth over the forecast period.
• Within the application category, pharmaceutical is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Red Seaweed Extract Market

The red seaweed extract market is undergoing a transformative period, driven by a global shift towards natural, sustainable, and health-benefiting ingredients. These trends reflect a concerted effort to leverage red seaweed’s unique properties, expanding its applications and addressing critical industry demands for innovative and environmentally responsible solutions.

• Growing Demand for Natural and Clean-Label Ingredients: Red seaweed extracts, such as carrageenan and agar, align with the clean-label movement as natural gelling, thickening, and stabilizing agents.
• Expansion in Nutraceuticals and Functional Foods: Increasing use of red seaweed in nutraceuticals and functional foods caters to health-conscious consumers seeking natural supplements.
• Emergence in Animal Feed and Aquafeed: Gaining traction as beneficial additives in animal feed, red seaweed extracts enhance growth and health in livestock, supporting sustainable agriculture.
• Increased Use in Agriculture: Recognized for enhancing crop growth and soil health, red seaweed extracts support sustainable farming practices.
• Research into Novel Bioactive Compounds: Ongoing research is uncovering pharmaceutical and biomedical applications, driving innovation in extraction techniques.

Recent Developments in the Red Seaweed Extract Market

The red seaweed extract market has experienced several key developments recently, reflecting its growing importance across various industries. These advancements are driven by consumer preference for natural ingredients, technological improvements, and understanding of seaweed’s diverse beneficial properties.

• Innovations in Cultivation Techniques: Sustainable cultivation methods are enhancing supply consistency and quality.
• Development of High-Purity Carrageenan and Agar: Higher purity grades cater to rigorous requirements in food, pharmaceutical, and cosmetic sectors.
• Expansion of Functional Food Applications: Seaweed extracts’ natural properties facilitate innovation in healthier food products.
• Discovery of New Bioactive Compounds: New compounds with health benefits are being identified, spurring novel nutraceutical and pharmaceutical usages.
• Sustainable Sourcing and Certifications: Emphasis on ethical sourcing enhances supply chain transparency and consumer trust.

Strategic Growth Opportunities in the Red Seaweed Extract Market

The red seaweed extract market offers compelling strategic growth opportunities across diverse applications, driven by its natural properties, functional versatility, and consumer demand for sustainable products.

• Food and Beverage Industry: Demand for natural thickeners and stabilizers presents growth opportunities, particularly in application-specific products.
• Nutraceuticals and Dietary Supplements: Providing functional ingredients for gut health and immunity offers high-growth potential.
• Personal Care and Cosmetics: The shift to natural beauty products offers opportunities for seaweed extracts in skincare and haircare formulations.
• Agriculture: Seaweed extracts as biostimulants open avenues for eco-friendly agricultural practices.
• Pharmaceuticals and Biomedical Applications: Exploring therapeutic properties and bioactive compounds offers long-term strategic gains.

Red Seaweed Extract Market Drivers and Challenges

The red seaweed extract market is influenced by factors such as the demand from food industries, health consciousness, and shifts towards natural products. However, challenges like raw material supply volatility and competition from substitutes impact growth.

The factors responsible for driving the red seaweed extract market include:

• Growing Demand from Food Industry: Red seaweed extracts are popular for their functional properties in food products.
• Increasing Health Consciousness: The nutritional benefits of seaweed drive demand in nutraceutical and functional food sectors.
• Shift Towards Natural and Plant-Based Products: The movement towards plant-based diets boosts the market for seaweed extracts.
• Technological Advancements in Extraction: Innovations enhance extract efficiency and purity for diverse applications.
• Expansion in Aquaculture and Animal Feed: Use in feeds promotes sustainable animal farming.

Challenges in the red seaweed extract market are:

• Raw Material Supply Volatility: Seasonal and environmental factors affect seaweed supply stability.
• Sustainability and Environmental Concerns: Responsible sourcing practices are vital amidst ecological implications of large-scale harvesting.
• Competition from Substitutes: Alternative hydrocolloids pose competition in terms of cost and functionality.

The red seaweed extract market is experiencing robust growth driven by its versatile applications in food, nutraceuticals, and personal care, aligning with consumer preferences for natural products. However, addressing challenges related to raw material supply sustainability, environmental impacts, and competition from alternatives will be crucial for ensuring long-term stability and continued expansion in this dynamic market.

List of Red Seaweed Extract Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies red seaweed extract companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the red seaweed extract companies profiled in this report include:

• DuPont
• Cargill
• Algaia
• Aquarev Industries
• Saosis Biotech
• Shemberg
• Qingdao Nanshan Seaweed
• Ceamsa
• Green Fresh Foodstuff
• Gelymar

Country-Wise Outlook for the Red Seaweed Extract Market

The red seaweed extract market is experiencing robust growth, primarily fueled by increasing awareness of its health benefits and diverse applications across various industries.

• United States: Driven by clean-label and plant-based trends with a focus on sustainable products.
• China: Experiences rapid growth supported by government and technological advancements.
• Germany: Focus on high-purity, sustainable products for food and pharmaceuticals.
• India: Development aided by government initiatives and increased awareness of seaweed benefits.
• Japan: Emphasizes high-value applications, innovative extraction methods, and research.

For more information about this report visit https://www.researchandmarkets.com/r/x7rj4c

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

OTC Pediatric Healthcare Market Report 2025-2031 Featuring Company Profiles of the Leading Players Across the Value Chain; Johnson & Johnson, Bayer, Amway, Sanofi, Procter & Gamble and More – ResearchAndMarkets.com




OTC Pediatric Healthcare Market Report 2025-2031 Featuring Company Profiles of the Leading Players Across the Value Chain; Johnson & Johnson, Bayer, Amway, Sanofi, Procter & Gamble and More – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “OTC Pediatric Healthcare Market Report: Trends, Forecast and Competitive Analysis to 2031” has been added to ResearchAndMarkets.com’s offering.

The global OTC pediatric healthcare market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are the increasing awareness of children’s health, the rising demand for self-medication in parents, and the growing availability of OTC pediatric products.

The future of the global OTC pediatric healthcare market looks promising with opportunities in the hospital pharmacy, drug store/pharmacy, and online pharmacy markets.

Key Highlights by Segment

• Within the type category, gastro intestinal is expected to witness the highest growth over the forecast period.
• Within the application category, online pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the OTC Pediatric Healthcare Market

The OTC pediatric healthcare market is evolving with significant trends reflecting changing consumer expectations, technological advances, and increased focus on wellness:

• Natural and Organic Products: Increasing demand for natural ingredients is pushing manufacturers to innovate using plant-based components.
• Online Retail Expansion: Digital channels and e-commerce are reshaping how parents purchase pediatric OTC products, enhancing convenience and choice.
• Preventive Healthcare Focus: There is a rising use of wellness and preventive products such as vitamins and probiotics tailored for children’s health.
• Personalization: Products are increasingly being tailored with age-specific formulations to offer better dosing accuracy and palatability.
• Integration with Digital Health Tools: Telehealth and digital tools are merging with OTC care to provide more accessible and informed healthcare decisions for parents.

These trends represent a shift toward consumer-centric, digital, and preventive health solutions, ensuring the sustained growth and relevance of the pediatric OTC market.

Recent Developments in the OTC Pediatric Healthcare Market

The market is undergoing rapid changes to improve product safety, efficacy, and accessibility:

• Enhanced Safety: Innovations in child-resistant packaging and safer formulations are addressing safety concerns.
• Expansion of E-commerce: Online platforms are significantly expanding the distribution channels for OTC products.
• Niche Product Growth: There is a surge in specialized pediatric formulations to enhance ease of use and compliance.
• Rise in Natural Remedies: There is an increased demand for homeopathic and natural remedies, reflecting a trend towards natural products.
• Focused Nutritional Supplements: The market for nutritional and immunity-boosting supplements for children is growing significantly.

Overall, these advancements are aligning with current consumer preferences for convenience, natural ingredients, and preventive healthcare.

Strategic Growth Opportunities in the OTC Pediatric Healthcare Market

Potential growth areas exist in expanding current product offerings and targeting emerging markets:

• Nutritional Supplements: Developing diverse and age-specific nutritional products can capture demand for preventive healthcare.
• Cough, Cold, and Allergy Remedies: Innovating in safer, effective formulations tailored for children remains a lucrative opportunity.
• Gastrointestinal Products: Leveraging demand for mild, pediatric-friendly gut health products presents significant potential.
• Dermatological and First Aid Products: Natural, hypoallergenic skin and first aid solutions are in demand.
• Pain and Fever Relief: Continued innovation in child-friendly pain relief formulations remains critical for market leadership.

Focusing on these strategies can enhance competitive positioning and support sustained market growth.

OTC Pediatric Healthcare Market Drivers and Challenges

The market is buoyed by technological advancements and consumer trends but faces regulatory and market challenges:

• Market Drivers:
  • Growing demand for self-medication and convenient access.
  • Prevalence of common childhood ailments ensuring steady demand.
  • Ongoing product innovations enhancing efficacy and safety.
  • Increased parental focus on child wellness and education.
  • Proliferation of e-commerce expanding market access.
• Market Challenges:
  • Stringent regulatory frameworks mandating rigorous safety standards.
  • Risks associated with misuse and incorrect dosing.
  • Competition from prescription and alternative therapies.

Addressing these challenges requires continued innovation, consumer education, and compliance with health standards to ensure market sustainability.

Country-Wise Outlook for the OTC Pediatric Healthcare Market

Regional markets provide unique opportunities and challenges:

• United States: High demand for natural products; significant digital platform usage.
• China: Rapid growth with emphasis on traditional and Western OTC products.
• Germany: Strong safety focus and digital integration driving market growth.
• India: Rising demand for pediatric-friendly formulations and online shopping.
• Japan: Continued innovation in pediatric analgesics and healthcare infrastructure.

Each country’s unique dynamics require tailored strategies for effective market engagement.

Company Profiles of the Leading Players Across the Value Chain

• Johnson & Johnson
• Bayer
• GlaxoSmithKline
• Pfizer
• Amway
• Reckitt Benckiser Group
• Sanofi
• Abbott Laboratories
• Procter & Gamble
• Church & Dwight

For more information about this report visit https://www.researchandmarkets.com/r/entboh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe




ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

• ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation for marketing authorization in Europe. For patients whose disease does not respond to BCG, there are currently no authorized treatment options; the primary option is surgical removal of the bladder.
• Unlike the U.S., where only one BCG substrain is approved, Europe recognizes and has approved approximately six major BCG substrains, making standard-of-care therapy broadly available across the region.¹
• The recommendation is based on the EMA’s determination that the benefit of making ANKTIVA available to patients now outweighs the risks associated with earlier access, providing an important option for adults with BCG-unresponsive NMIBC, and builds on existing approvals in the U.S. and United Kingdom.
• Each year, more than 150,000 people in Europe are diagnosed with NMIBC.²

CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA^® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. This recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder.

“ANKTIVA represents an important evolution in the treatment of NMIBC CIS, strengthening the immune response and improving the durability of BCG,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible, to ensure avoidance of a radical cystectomy. We are pleased that the EMA issued this positive recommendation based on our single-arm trial and through a regulatory process that allows earlier access to ANKTIVA, when as stated in the EMA announcement, the benefit of a medicine’s immediate availability to patients outweighs the inherent risks.”

“ANKTIVA offers a new treatment option for patients and addresses an important unmet need,” the EMA noted in an announcement on the recommendation. “There are currently no authorised treatments for NMIBC that does [sic] not respond to BCG.”

Bladder cancer is a serious public health concern in the European Union, ranking as the fifth-most common cancer and the seventh most frequently diagnosed cancer in men.^2,3 The European Association of Urology and World Bladder Cancer Patient Coalition estimate that more than 200,000 patients will be diagnosed with bladder cancer in 2025.⁴ Approximately 75% of these patients (150,000) will have NMIBC, which is cancer that has grown only on the lining of the bladder and not into the muscle layer underneath, and is the most common form of bladder cancer.

“We are looking forward to finalizing plans to bring our innovative treatment to qualified EU patients,” said Richard Adcock, President and CEO of ImmunityBio. “With the United States’ new Most-Favored-Nation Prescription Drug Pricing policy now in effect, we are thoughtfully assessing our approach to launching in Europe to ensure broad, equitable, and sustainable access.”

The decision was based on a review of the results of a single-arm clinical trial in 100 adults with BCG-unresponsive NMIBC who received ANKTIVA in combination with BCG. In 71% of patients, signs of cancer disappeared (complete response rate) with responses ranging up to 54+ months; these responses lasted for approximately 27 months on average. The complete response rate of responders at 12 months was 66% and at 24 months was 42%. As part of the recommendation, ImmunityBio will continue to follow up with trial participants and submit long-term safety and efficacy post-marketing results to the EMA.

“Six BCG strains are available in Europe for use in combination with ANKTIVA, and we are expeditiously developing our recombinant BCG candidate to address ongoing BCG shortages in the U.S. and help ensure that all eligible patients can benefit from this treatment,” said Adcock.

ANKTIVA has been recommended for a conditional marketing authorization, an EU regulatory mechanism designed to facilitate early access to medicines that address an unmet medical need. This pathway allows the EMA to recommend marketing authorization when the benefit of a medicine’s immediate availability to patients outweighs the potential risks associated with the data, in this case, from a single-arm trial. The EMA’s opinion will now be forwarded to the European Commission for final approval of EU-wide marketing authorization.

U.S. IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes.

Please see the complete Prescribing Information for ANKTIVA^® at Anktiva.com.

About ImmunityBio

ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit ImmunityBio.com (Founder’s Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.

1. Guallar-Garrido S. and Julián E. Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update. Immunotargets Ther. 2020 Feb 13;9:1–11. Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC7025668
2. European Association of Urology. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Limited Update March 2025. Available at https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer/chapter/epidemiology-aetiology-and-pathology
3. European Association of Urology. Bladder Cancer: The Forgotten Cancer. Sep 2022. Available at https://uroweb.org/news/bladder-cancer-the-forgotten-cancer
4. World Bladder Cancer Patient Coalition, EAU. Tackling Bladder Cancer in Europe. February 2025. Available at https://worldbladdercancer.org/wp-content/uploads/2025/03/WBCPC-EAU-Bladder-Cancer-MEP-A4-2025-Digital59.pdf

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the European Commission’s recommendation facilitating early access to medicine and the benefits of the immediate availability of ANKTIVA, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, the application of the Company’s science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, the Company’s ability to distribute treatment broadly to patients in the EU, the Company’s follow up with trial participants and the submission of long-term trial results to the EMA, the European Commission’s recommendation of final approval of broader marketing of ANKTIVA^®, the Company’s development of a recombinant Bacillus Calmette-Guérin (BCG) candidate to address BCG shortages to ensure that patients access to treatment, and ImmunityBio’s approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “is,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions.

Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio’s ability to retain and hire key personnel, (viii) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio’s ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio’s ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company’s Form 10-Q filed with the SEC on November 5, 2025 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

Contacts

ImmunityBio Contacts:

Investors
Hemanth Ramaprakash, PhD, MBA
ImmunityBio, Inc.
+1 858-746-9289

Hemanth.Ramaprakash@ImmunityBio.com

Media
Sarah Singleton
ImmunityBio, Inc.
+1 415-290-8045

Sarah.Singleton@ImmunityBio.com